Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer

Memorial Sloan Kettering Cancer Center (MSK)

Status and phase

Completed

Phase 1

Conditions

Breast Cancer

Treatments

Other: Blood draw

Diagnostic Test: F-Var3 PET/CT

Study type

Interventional

Funder types

Other

Identifiers

NCT04054986

19-147

Details and patient eligibility

About

The purpose of this study is to measure the safety of the investigational imaging agent, 18F-Var3 and to determine if it is helpful in providing information about how tumor tissues behave.

Enrollment

6 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 18 years or greater
Biopsy-proven breast malignancy
>/= 1 viable lesion, >/= 1 cm, confirmed on CT, MR, or FDG PET/CT within 4 weeks of protocol enrollment
Newly diagnosed or recurrent disease, on or off therapy
ECOG performance of 0-2 *Note: Lesions are considered viable if they are stable or increasing soft tissue lesions, or if they are FDG-avid bone lesions

Exclusion criteria

Life expectancy < 3 months
Pregnancy or lactation
Biopsy or other surgical procedures within 48 hours prior to receiving study intervention
Patients who cannot undergo PT/CT scanning because of weight limits. PET/CT scanners may not be able to function with patients over 400 pounds